Direct Answer
McKesson Corporation (MCK) is one of the largest US pharmaceutical distributors, moving drugs from manufacturers to pharmacies, hospitals, and healthcare providers at massive scale. Revenue is enormous but margins are thin because drug distribution is a low-margin logistics business; earnings come from scale purchasing advantages, generic drug economics, and ancillary services. McKesson settled opioid litigation for approximately $7.4 billion in 2022.
McKesson Corporation (MCK) Business & Investor Dossier
Company Snapshot
| Ticker | MCK (NYSE) |
|---|---|
| Founded | 1833, New York, New York |
| Headquarters | Irving, Texas |
| Sector | Health Care |
| Industry | Health Care Distributors |
| Business | Pharmaceutical and medical supply distribution |
| Key Segments | US Pharmaceutical; Prescription Technology Solutions; Medical-Surgical |
| Revenue Scale | ~$310B+ annual revenue (one of world's largest companies by revenue) |
| Key Settlement | ~$7.4B opioid settlement (2022) |
| Key Competitors | AmerisourceBergen (Cencora), Cardinal Health |
What Does McKesson Do?
McKesson is one of the three dominant US pharmaceutical distributors (alongside Cencora and Cardinal Health), collectively handling the vast majority of drug distribution in the United States. The company buys drugs from pharmaceutical manufacturers in bulk and distributes them to retail pharmacies (CVS, Walgreens, independents), hospital systems, and other healthcare facilities. McKesson also operates medical-surgical supply distribution and healthcare technology services.
The business generates revenues in the hundreds of billions of dollars annually -- making McKesson consistently one of the highest-revenue companies in the US -- but profit margins are thin because drug distribution is a logistics fee business, not a drug-pricing business.
The Three-Party Distribution System
The US pharmaceutical supply chain relies on distributors as essential intermediaries. Drug manufacturers prefer to deal with a few large distributors rather than thousands of pharmacies individually; pharmacies and hospitals prefer to source from distributors rather than maintaining hundreds of direct manufacturer relationships. McKesson provides temperature-controlled storage, regulatory compliance, inventory management, and rapid delivery logistics. This role is deeply embedded in the healthcare supply chain and difficult to disintermediate.
Frequently Asked Questions
How does McKesson make money?
McKesson makes money primarily as a pharmaceutical distributor -- buying drugs from manufacturers at wholesale prices and reselling them to pharmacies, hospitals, and other healthcare providers. The core distribution business earns a fee-for-service spread plus additional income from buying at discount and selling at a markup (especially on generic drugs, where McKesson's scale gives it purchasing power). McKesson also operates McKesson Medical-Surgical (a medical supply distributor) and Prescription Technology Solutions (pharmacy technology and services). Revenue is enormous relative to profit margins because the distribution business is high-volume, low-margin.
What is the drug distribution model and why is it low margin?
Drug distributors like McKesson act as logistics intermediaries between manufacturers and dispensers. They buy from manufacturers, warehouse drugs, and deliver to pharmacies and hospitals, earning a small percentage of the drug's price as distribution fee. Because drug prices are high and margins are thin (often under 1% of revenues), drug distributors have enormous revenues relative to profit. The business benefits from high volume, the non-discretionary nature of prescription drugs, and scale advantages in warehousing, logistics, and purchasing, but is not a high-margin business in absolute percentage terms.
What is McKesson's generic drug economics advantage?
McKesson earns its best margins on generic drugs, where it negotiates bulk purchasing agreements with generic manufacturers and can sell at prices above its acquisition cost. Generic drug purchasing is a scale game: McKesson's enormous volume gives it the leverage to negotiate favorable prices from generic drug makers. When generic drug prices decline (due to increased competition or regulatory action), McKesson's generic margins compress. When generic launches of newly off-patent branded drugs occur, McKesson benefits from the initial high margins before generic competition normalizes pricing.
What is the opioid litigation impact on McKesson?
McKesson was a major defendant in opioid litigation brought by state and local governments, alleging that drug distributors failed to detect and report suspicious ordering patterns that contributed to the opioid crisis. McKesson settled for approximately $7.4 billion as part of a broader $21 billion settlement with three major distributors (McKesson, Cardinal Health, AmerisourceBergen) reached in 2022. The settlement included cash payments over 18 years and operational changes in drug distribution compliance. While expensive, the settlement resolution removed major litigation overhang from McKesson's valuation.
What are the main risks for McKesson?
Main risks include drug pricing reform (government or payer-driven compression of drug prices would directly affect distribution economics), generic drug price deflation (ongoing competition in generics reduces McKesson's spread income), customer concentration (large pharmacy chains and hospital systems have significant negotiating leverage), regulatory changes to drug distribution requirements, and cybersecurity exposure given the sensitive healthcare data McKesson handles. The business is also sensitive to pharmaceutical industry dynamics -- branded drug pricing trends, generic launches, and specialty drug growth all affect the mix of McKesson's distribution volumes.